f Cancerous Inhibitor of Phosphatase 2A (CIP2A): A Sensitive Diagnostic Marker and Therapeutic Agent in Oral Cancer

References

1. NiY. DingL. HuQ. HuaZ-C. Potential biomarkers for oral squamous cell carcinoma: Proteomics discovery and clinical validation.Proteomics Clin. Appl.201591-2869710.1002/prca.201400091
   [Google Scholar]
2. BadwelanM. MuaddiH. AhmedA. LeeK.T. TranS.D. Oral squamous cell carcinoma and concomitant primary tumors, what do we know? A review of the literature.Curr. Oncol.20233043721373410.3390/curroncol30040283 37185396
   [Google Scholar]
3. AlzahraniR. AlrehailiA.A. GharibA.F. AnjumF. IsmailK.A. ElsawyW.H. Cancerous inhibitor of protein phosphatase 2A as a molecular marker for aggressiveness and survival in oral squamous cell carcinoma.J. Cancer Prev.2020251212610.15430/JCP.2020.25.1.21 32266176
   [Google Scholar]
4. MyantK. QiaoX. HalonenT. ComeC. LaineA. PartanenJ.I. OggE-L. LaiteräT. JanghorbanM. OkkeriJ. KlefströmJ. SearsR.C. SansomO.J. WestermarckJ. Abstract PR03: Serine 62 phosphorylated MYC associates with nuclear lamins and its regulation by CIP2A is essential for proliferation induction in vivo.Mol. Cancer Res.20151310_SupplementPR0310.1158/1557‑3125.MYC15‑PR03
   [Google Scholar]
5. ChenB. HuH. ChenX. From basic science to clinical practice: The role of cancerous inhibitor of protein phosphatase 2A (CIP2A)/p90 in cancer.Front. Genet.202314111065610.3389/fgene.2023.1110656 36911405
   [Google Scholar]
6. KhanM.M. UllahU. KhanM.H. KongL. MoulderR. VälikangasT. BhosaleS.D. KomsiE. RasoolO. ChenZ. EloL.L. WestermarckJ. LahesmaaR. CIP2A constrains Th17 differentiation by modulating STAT3 signaling.iScience202023310094710.1016/j.isci.2020.100947 32171124
   [Google Scholar]
7. TarekM.M. YahiaA. El-NakibM.M. ElhefnawiM. Integrative assessment of CIP2A overexpression and mutational effects in human malignancies identifies possible deleterious variants.Comput. Biol. Med.202113910498610.1016/j.compbiomed.2021.104986 34739970
   [Google Scholar]
8. KimD.H. LeeJ. LeeM.H. KimS.W. HwangS.H. Efficacy of chemiluminescence in the diagnosis and screening of oral cancer and precancer: A systematic review and meta-analysis.Rev. Bras. Otorrinolaringol.202288335836410.1016/j.bjorl.2020.06.011 32847738
   [Google Scholar]
9. HuangT.T. ChenK.C. WongT.Y. ChenC.Y. ChenW.C. ChenY.C. ChangM.H. WuD.Y. HuangT.Y. NiokaS. ChungP.C. HuangJ.S. Two-channel autofluorescence analysis for oral cancer.J. Biomed. Opt.201824511010.1117/1.JBO.24.5.051402 30411551
   [Google Scholar]
10. XianM. StephanyJ.L. ChiuC.W. ChiangC.C. RenF. TsaiC.T. ShanS.S. LiaoY.T. Esquivel-UpshawJ.F. PeartonS.J. High sensitivity CIP2A detection for oral cancer using a rapid transistor-based biosensor module.J. Vac. Sci. Technol. B Nanotechnol. Microelectron.202341101320110.1116/6.0002175 36531804
    [Google Scholar]
11. Alexander-BryantA.A. DumitriuA. AttawayC.C. YuH. JakymiwA. Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo.J. Control. Release2015218728110.1016/j.jconrel.2015.09.026 26386438
    [Google Scholar]
12. LinY.C. ChenK.C. ChenC.C. ChengA.L. ChenK.F. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.Oral Oncol.201248758559310.1016/j.oraloncology.2012.01.012 22342571
    [Google Scholar]
13. ZhaoM. HowardE.W. ParrisA.B. GuoZ. ZhaoQ. MaZ. XingY. LiuB. EdgertonS.M. ThorA.D. YangX. Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells.Oncotarget2017835588475886410.18632/oncotarget.19375 28938602
    [Google Scholar]
14. LiuZ. MaL. WenZ.S. HuZ. WuF.Q. LiW. LiuJ. ZhouG.B. Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer.Carcinogenesis201435490591410.1093/carcin/bgt395 24293411
    [Google Scholar]